HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lawrence Blonde Selected Research

Hypoglycemic Agents (Hypoglycemics)

11/2020Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
11/2019Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
7/2018Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations.
6/2018Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
1/2018Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
1/2016A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
12/2014Fixed-dose combination therapy in type 2 diabetes mellitus.
10/2014Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetes.
4/2013The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
1/2013The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lawrence Blonde Research Topics

Disease

83Type 2 Diabetes Mellitus (MODY)
10/2022 - 01/2002
24Hypoglycemia (Reactive Hypoglycemia)
11/2020 - 04/2004
15Body Weight (Weight, Body)
10/2022 - 05/2008
11Weight Gain
01/2021 - 12/2004
11Weight Loss (Weight Reduction)
05/2016 - 11/2006
6Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 10/2012
5Heart Failure
01/2022 - 10/2012
5Nausea
11/2020 - 07/2009
5Diabetes Complications
01/2012 - 10/2002
5Hyperglycemia
03/2010 - 04/2003
4Insulin Resistance
10/2021 - 10/2002
4Dyslipidemias (Dyslipidemia)
05/2014 - 08/2005
4Hypertension (High Blood Pressure)
05/2014 - 08/2005
3Diabetes Mellitus
10/2014 - 11/2006
2Body Weight Changes
11/2020 - 01/2020
2Vomiting
11/2019 - 05/2015
2Type 1 Diabetes Mellitus (Autoimmune Diabetes)
12/2017 - 12/2004
2Metabolic Diseases (Metabolic Disease)
01/2015 - 11/2006
2Myocardial Infarction
01/2015 - 10/2012
2Stroke (Strokes)
01/2015 - 10/2012
1Kidney Diseases (Kidney Disease)
01/2022
1Pneumonia (Pneumonitis)
05/2015
1Ventricular Fibrillation
05/2015
1Cardiogenic Shock
05/2015
1Fibrosis (Cirrhosis)
10/2014
1Chronic Renal Insufficiency
10/2014
1Sepsis (Septicemia)
10/2014
1Neoplasms (Cancer)
11/2013
1Unstable Angina
10/2012
1Prediabetic State (Prediabetes)
11/2011
1Schizophrenia (Dementia Praecox)
05/2008
1Heart Diseases (Heart Disease)
05/2008

Drug/Important Bio-Agent (IBA)

39Insulin (Novolin)FDA Link
01/2022 - 10/2004
22Glucose (Dextrose)FDA LinkGeneric
01/2022 - 10/2002
20Hypoglycemic Agents (Hypoglycemics)IBA
11/2020 - 04/2004
16Insulin Glargine (Lantus)FDA Link
01/2022 - 04/2013
15Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
10/2022 - 10/2002
13Glucagon-Like Peptide 1 (GLP 1)IBA
10/2022 - 02/2009
13Glucagon-Like Peptide-1 ReceptorIBA
01/2021 - 07/2009
12LiraglutideFDA Link
10/2021 - 02/2009
11CanagliflozinIBA
01/2021 - 01/2014
11Metformin (Glucophage)FDA LinkGeneric
01/2021 - 04/2004
9SodiumIBA
01/2022 - 05/2014
9Blood Glucose (Blood Sugar)IBA
11/2020 - 01/2002
8lixisenatideIBA
01/2022 - 01/2017
7Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2022 - 12/2009
6Exenatide (Byetta)FDA Link
11/2019 - 07/2009
6LipidsIBA
08/2018 - 01/2005
5SymportersIBA
01/2021 - 04/2015
5Sitagliptin Phosphate (Januvia)FDA Link
11/2020 - 01/2013
4Hemoglobins (Hemoglobin)IBA
06/2021 - 11/2008
4insulin degludecIBA
01/2021 - 04/2013
4Pharmaceutical PreparationsIBA
07/2018 - 07/2009
4glimepiride (Amarel)FDA LinkGeneric
05/2016 - 02/2009
4oxidized low density lipoproteinIBA
11/2015 - 01/2014
4Bromocriptine (Parlodel)FDA LinkGeneric
01/2015 - 11/2011
3Sodium-Glucose Transporter 2 InhibitorsIBA
01/2021 - 05/2014
3InsulinsIBA
11/2019 - 05/2014
3dulaglutideIBA
11/2019 - 05/2015
3LDL CholesterolIBA
11/2015 - 01/2014
3Insulin Lispro (Humalog)FDA Link
05/2015 - 05/2014
3IncretinsIBA
11/2011 - 09/2006
2semaglutideIBA
10/2022 - 11/2020
2empagliflozinIBA
01/2021 - 11/2020
2dapagliflozinIBA
01/2021 - 01/2018
2IDegLiraIBA
11/2020 - 04/2016
2rGLP-1 proteinIBA
11/2019 - 01/2017
2Sodium-Glucose Transport ProteinsIBA
11/2019 - 01/2014
2ThiazolidinedionesIBA
01/2018 - 10/2002
2Triglycerides (Triacylglycerol)IBA
02/2015 - 01/2013
2CholesterolIBA
02/2015 - 01/2012
2Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
01/2015 - 10/2012
2Protamines (Protamine Sulfate)FDA Link
05/2014 - 05/2014
2Nonesterified Fatty Acids (NEFA)IBA
01/2013 - 11/2006
2Rosiglitazone (Avandia)FDA Link
07/2009 - 02/2009
1Peptides (Polypeptides)IBA
10/2022
1CreatinineIBA
06/2021
1Pioglitazone (Actos)FDA Link
11/2019
1omega-Chloroacetophenone (Mace)IBA
08/2018
1Insulin Detemir (Levemir)FDA Link
01/2018
1Urea (Carbamide)FDA LinkGeneric
01/2016
1HDL CholesterolIBA
11/2015
1EnzymesIBA
02/2015
1SympatholyticsIBA
01/2015
1ORALIT (ORS)IBA
10/2014
1Glucagon-Like Peptides (Enteroglucagon)IBA
05/2014
1Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA
05/2014
1Isophane Insulin (NPH Insulin)FDA Link
05/2014
1Dipeptidyl-Peptidase IV InhibitorsIBA
05/2014
1Human Isophane InsulinFDA Link
11/2013
1SecretagoguesIBA
11/2011
1Colesevelam Hydrochloride (Welchol)FDA Link
11/2011
12,4-thiazolidinedione (thiazolidinedione)IBA
07/2009
1Dihydrotachysterol (AT 10)IBA
05/2008

Therapy/Procedure

36Therapeutics
01/2022 - 10/2002
24Glycemic Control
10/2022 - 01/2002
4Injections
11/2020 - 10/2004
2Drug Therapy (Chemotherapy)
07/2018 - 03/2010
2Nutrition Therapy (Medical Nutrition Therapy)
03/2010 - 11/2006
1Length of Stay
10/2014